Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 6/20 | 0.41 |
| ▸ | PREP | P48147 | 6/20 | 0.41 |
| ▸ | DPP4 | P27487 | 5/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 5/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330609 | 1.00 | FAP (0.41) | FAPPREPDPP4ACENPSR1 | |
| SCHEMBL464681 | 0.87 | PREP (0.55) | FAPPREPDPP4NPSR1F2 | |
| SCHEMBL1046072 | 0.85 | DPP4 (0.46) | FAPPREPDPP4ACENPSR1 | |
| SCHEMBL1046070 | 0.85 | DPP4 (0.46) | FAPPREPDPP4ACENPSR1 | |
| SCHEMBL20908682 | 0.84 | F2 (0.48) | FAPPREPDPP4NPSR1F2 | |
| SCHEMBL21779485 | 0.83 | DPP4 (0.47) | FAPPREPDPP4ACE | |
| SCHEMBL12809058 | 0.83 | DPP4 (0.47) | FAPPREPDPP4ACE | |
| SCHEMBL11515849 | 0.82 | F2 (0.40) | FAPPREPDPP4NPSR1F2 | |
| SCHEMBL11515844 | 0.82 | F2 (0.40) | FAPPREPDPP4NPSR1F2 | |
| SCHEMBL11111422 | 0.81 | CHRM2 (0.40) | FAPPREPDPP4NPSR1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2009-07-02 | — | — | US | disclosed |
| CN-100382795-C | Glycinamide derivative for inhibiting HIV replication | TRIPEP AB (SE) | 2008-04-23 | — | — | CN | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1799222-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060188920-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | BALZARINI JAN MARIA R | 2006-08-24 | — | — | US | disclosed |
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | BALZARINI JAN MARIA R | 2006-08-17 | — | — | US | disclosed |
| CN-1777414-A | Glycinamide derivative for inhibiting HIV replication | TRIPEP AB (SE) | 2006-05-24 | — | — | CN | disclosed |
| WO-2006030323-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2006-03-23 | — | — | WO | disclosed |
| EP-1603546-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | Tripep AB (SE) | 2005-12-14 | — | — | EP | disclosed |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | TRIPEP AB (SE) | 2005-05-05 | — | — | US | disclosed |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | TRIPEP AB (SE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004073703-A1 | GLYCINAMIDE DERIVATIVE FOR INHIBITING HIV REPLICATION | TRIPEP AB (SE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | GALE, ENGASE, GLMN | FAP 1534/4885PREP 35/4885DPP4 625/4885 |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | GALE, ENGASE, GLMN | FAP 1297/4885PREP 16/4885DPP4 449/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | FAP 1312/4885PREP 7/4885DPP4 725/4885 |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | ENGASE, GALE, OGA | FAP 1000/4885PREP 10/4885DPP4 380/4885 |
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | OGA, ENGASE, GALE | FAP 1612/4885PREP 21/4885DPP4 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.